The Personalised Medicine Consortium (PMC) of Luxembourg is an initiative aiming to support research and make Luxembourg a leader in the adoption of personalised medicine into the national healthcare system. It brings together the Luxembourg Institute of Health (LIH), the LCSB (Luxembourg Centre for Systems Biomedicine), IBBL (Integrated BioBank of Luxembourg), the Laboratoire National de Santé (LNS) and the Life Sciences Research Unit (LSRU) of the University of Luxembourg (UNI).

The PMC is led by an Executive Board consisting of Ulf Nehrbass (CEO of LIH and CEO ad interim of IBBL), Paul Wilmes (LCSB), Friedrich Mühlschlegel (CEO of LNS) and Iris Behrmann (Prof LSRU/UNI). The PMC’s initial areas of focus were cancer, diabetes and Parkinson’s disease and multiple collaborative projects were successfully launched and executed. Recently, the scope of the PMC has been extended to include other diseases and areas of interest (e.g. big data).

The PMC Fund

The PMC is keen to build new collaborations between clinicians and researchers from Luxembourg and foster new synergies. To aid in this process, the PMC has developed a fund to ‘pump prime’ new initiatives. This programme was successfully launched in 2014/2015 and a new call for 2020/21 is currently being discussed by the Executive Board.

The expectation is that the funding will be used to initiate new collaborative biomedical research projects between clinicians and researchers based in different research institutions. Priority will be given to projects that are novel and innovative, that are establishing new collaborations in Luxembourg and where preliminary data is needed prior to submitting an application to an external funding agency.

The main expected return on investment of such funding relies on:

  • Solving unmet clinical needs with an innovative approach
  • Fostering research interactions between the three biomedical research institutes of Luxembourg
  • Enabling researchers/clinicians to develop this project into an externally funded project if successful

Practical Information

A minimum of two of the PMC funding organisations (IBBL-LIH-LCSB-LNS-LSRU/UNI) must be involved in each funding application (ideally more). For full details about the call, the conditions of eligibility and the application process, you can download the PMC FUND Overview & Guidelines.

Call deadlines

The 2020/21 call for proposals is still being discussed by the Executive Board and more information will be published soon.

Call documents

2019/20 PMC FUND Overview & Guidelines:
Download PDF

2019/20 PMC FUND Application Form:
Download PDF


If you have any questions, please contact Clair MEEK:

Tel:  +352 26 970 – 549


You may be interested in:

  • IBBL confirms its leading role in personalised medicine with [...]

    Codex4SMEs project aims to build networks between academic world and industry.IBBL (Integrated BioBank of Luxembourg) will over […]

  • Loss of Myosin Vb in colorectal cancer is a [...]

    E. Letellier, M. Schmitz, A. Ginolhac, F. Rodriguez, P. Ullmann, K. Qureshi-Baig, S. Frasquilho, L. Antunes, S. […]

  • Shaping Europe’s Vision for Personalised Medicine

    Considered a European expert on biomarkers, IBBL’s CEO, Dr Catherine Larue, was asked to contribute to the […]